)
Visual24 Oct 2025
The rise of Alphabet
Citius Pharmaceuticals (CTXR) investor relations material
Citius Pharmaceuticals Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary12 Aug, 2025
Executive summary
No revenues generated for the quarter or nine months ended June 30, 2025; focus remains on commercial launch of LYMPHIR in Q4 2025.
Net loss for the quarter was $9.2 million, an improvement from $10.6 million in the prior year quarter; nine-month net loss was $31.0 million, up from $28.3 million year-over-year.
Transitioning from development-stage to commercial organization, with major launch activities completed for LYMPHIR, including manufacturing and distribution agreements.
Company completed a merger recapitalization, resulting in a 92.3% ownership of Citius Oncology.
Continued engagement with FDA for Mino-Lok and Halo-Lido programs; Mino-Lok met Phase 3 endpoints.
Financial highlights
Operating loss for the quarter was $8.8 million, down from $10.6 million year-over-year; nine-month operating loss was $30.1 million, down from $30.9 million.
R&D expenses decreased to $1.6 million from $2.8 million year-over-year; G&A expenses were $4.4 million, down from $4.8 million.
Stock-based compensation expense for the quarter was $2.7 million, down from $3.1 million year-over-year.
Cash and cash equivalents at June 30, 2025 were $6.1 million.
Net cash used in operations for nine months was $14.7 million; net proceeds from equity and note financings totaled $17.5 million.
Outlook and guidance
Management expects R&D expenses to decrease further as focus shifts to commercialization of LYMPHIR.
Sufficient funds are expected to support operations through September 2025, but additional capital will be needed beyond that period.
Commercial launch of LYMPHIR in the U.S. is planned for Q4 2025, targeting cutaneous T-cell lymphoma, with distribution agreements in place.
Ongoing FDA engagement for Mino-Lok and Halo-Lido; next steps being outlined.
Assess LYMPHIR's market readiness for Q4 2025 launch.
Explain the strategy for Mino-Lok's FDA engagement.
How will Citius fund operations beyond September 2025?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Citius Pharmaceuticals earnings date
2025 ThinkEquity Conference30 Oct, 2025
Next Citius Pharmaceuticals earnings date
2025 ThinkEquity Conference30 Oct, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing critical care products. The company's pipeline includes a range of therapeutic candidates targeting various medical needs. Key products include Mino-Lok, an antibiotic lock solution designed to salvage central venous catheters in patients with catheter-related bloodstream infections, and LYMPHIR, a targeted immunotherapy recently approved by the FDA for treating relapsed or refractory cutaneous T-cell lymphoma (CTCL). Another notable product is CITI-002 (Halo-Lido), a topical formulation aimed at providing relief for hemorrhoids. The company is based in Cranford, New Jersey, and its shares are traded on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage